Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
DHR - Danaher Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$223.63
DETAILS
HIGH:
$249.00
LOW:
$200.00
MEDIAN:
$230.00
CONSENSUS:
$223.63
UPSIDE:
11.38%
Stock News
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
VTRS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?
Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.
Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios
Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP). The funding will be distributed across the three organizations to enable rapid, flexible response to evolving conditions on the ground.
The Big 3: JPM, DHR, MRK
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in Merck (MRK).
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors
Danaher (DHR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DHR crossed above the 20-day moving average, suggesting a short-term bullish trend.
Danaher Is Down 22% This Year. Is the Masimo Acquisition the Entry Point Investors Have Been Waiting for?
The company is seeing a big uptick in equipment orders. Danaher said it expects its acquisition of Masimo to be accretive to earnings this year.
VTRS vs. DHR: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher Schedules Second Quarter 2026 Earnings Conference Call
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour.
The Best Stocks to Invest $1,000 in Right Now
Exploring some of the top bargains in a multi-trillion-dollar industry.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core revenue gains expected in 2026.
Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The "Buy the Dip" traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to... Here Are Thursday's Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Danaher Completes Acquisition of Masimo Corporation
WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio.
Price Targets
Danaher price target lowered to $230 from $232 at Evercore ISI
$230.00
(was $190.60)
Vijay Kumar
·
Evercore ISI
Danaher initiated with a Neutral at Piper Sandler
$200.00
(was $183.63)
Piper Sandler
Danaher price target lowered to $230 from $270 at HSBC
$230.00
(was $176.11)
HSBC
Danaher resumed with an Outperform at RBC Capital
$200.00
(was $164.54)
RBC Capital
Danaher price target raised to $245 from $240 at Jefferies
$245.00
(was $194.45)
Tycho Peterson
·
Jefferies
Danaher price target lowered to $249 from $251 at Baird
$249.00
(was $193.78)
Catherine Ramsey Schulte
·
Robert W. Baird
Danaher price target lowered to $205 from $220 at Rothschild & Co Redburn
$205.00
(was $193.78)
Redburn Partners
Danaher price target lowered to $230 from $250 at Barclays
$230.00
(was $195.87)
Barclays
Danaher price target raised to $251 from $247 at Baird
$251.00
(was $224.54)
Robert W. Baird
Danaher price target raised to $265 from $255 at Jefferies
$265.00
(was $224.54)
Jefferies
Danaher price target raised to $254 from $250 at Evercore ISI
$254.00
(was $224.47)
Vijay Kumar
·
Evercore ISI
Danaher price target raised to $265 from $255 at Argus
$265.00
(was $235.56)
Argus Research
Danaher price target raised to $250 from $245 at Evercore ISI
$250.00
(was $231.72)
Vijay Kumar
·
Evercore ISI
Danaher price target raised to $240 from $230 at Wells Fargo
$240.00
(was $226.71)
Wells Fargo
Danaher initiated with a Buy at Goldman Sachs
$265.00
(was $224.48)
Goldman Sachs
Danaher initiated with an Overweight at Morgan Stanley, named Top Pick in group
$270.00
(was $224.14)
Morgan Stanley
Danaher price target raised to $230 from $205 at Wells Fargo
$230.00
(was $218.10)
Wells Fargo
Danaher price target raised to $247 from $236 at Baird
$247.00
(was $220.77)
Robert W. Baird
Danaher downgraded to Neutral from Buy at Rothschild & Co Redburn
$220.00
(was $208.77)
Redburn Partners
Danaher price target lowered to $241 from $250 at RBC Capital
$241.00
(was $203.79)
RBC Capital